サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1436572

ペプチド治療薬の世界市場レポート (2024年)

Peptide Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ペプチド治療薬の世界市場レポート (2024年)
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ペプチド治療薬の市場規模は、今後数年間で急速に成長すると予想されています。今後は10.8%の年間複合成長率 (CAGR) で成長し、2028年には688億3,000万米ドルに成長すると予想されます。予測期間で予想される成長は、個別化医療の需要増大、免疫療法の適用拡大、ペプチド送達システムの進歩、感染症における新たなペプチド標的、希少疾患への関心増大によるものと考えられます。予測期間の主な動向には、ペプチド合成における技術進歩、投資と資金の増加、ペプチド医薬品の安全性の重視、新興国での市場拡大、人工知能 (AI) の統合が含まれます。

ペプチド治療薬市場は、主に慢性疾患の蔓延によって成長が見込まれています。長期にわたる、しばしば不治の性質を特徴とする慢性疾患は、タバコ製品の使用量の増加、最適とは言えない栄養状態、運動不足、過度のアルコール摂取などの要因によって増加しています。慢性疾患は治療が困難ですが、管理することができ、場合によっては制御することができます。ペプチド治療薬の利用は、特定の慢性疾患の予防と治療の両方において重要な役割を果たします。特に、2023年1月、米国の国立医学図書館は、米国に関する重要な予測を報告し、少なくとも1つの慢性疾患を持つ50歳以上の人の数が99.5%急増し、2050年には1億4,266万人に達する、と予想しています。 その結果、慢性疾患の有病率の増加見通しは、予測期間全体を通じてペプチド治療薬市場の成長の主要な原動力となると考えられます。

ペプチド治療薬市場の成長軌道は、高齢者人口の増加によって大きく影響を受けると予想されます。 65歳以上の個人として定義される高齢者人口は、さまざまな健康状態の有病率が高いことに直面しています。ペプチド治療薬は、加齢に伴う疾患に関連する特定の経路を標的にし、骨密度を改善し、骨折のリスクを軽減することにより、これらの症状の管理と治療において極めて重要な役割を果たします。特に、世界保健機関が2022年10月に強調した世界の人口動態動向は、6人に1人が2030年までに60歳以上となり、2050年までにこの年齢層は2倍の21億人になると予測されています。特定の地域への影響により、英国議会の下院図書館は2021年 6月に、英国の高齢者人口が増加し、2043年までに総人口の24% (1,740万人) を占めると予想されると報告しました。この人口動態の変化は、高齢者の医療ニーズに対応する上でペプチド治療薬の重要性が高まっていることを強調しています。 その結果、高齢者人口の増加が近い将来、ペプチド治療薬市場の成長を推進する重要な推進力として浮上します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の市場規模と成長

  • 世界のペプチド治療薬市場の促進要因と抑制要因
    • 市場の促進要因
    • 市場の抑制要因
  • 世界のペプチド治療薬の市場規模と成長の実績、2018～2023年
  • 世界のペプチド治療薬の市場規模と成長の予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のペプチド治療薬市場、種類別セグメンテーション、実績・予測、2018年～2023年、2023～2028年、2033年
  • ジェネリック
  • ブランド
  • 世界のペプチド治療薬市場、投与経路別セグメンテーション、実績・予測、2018年～2023年、2023～2028年、2033年
  • 非経口
  • 粘膜
  • 経口
  • 経皮
  • 世界のペプチド治療薬市場、用途別セグメンテーション、実績・予測、2018年～2023年、2023～2028年、2033年
  • がん
  • 心血管疾患
  • 中枢神経系
  • 代謝障害
  • 感染症
  • 血液疾患
  • 胃腸疾患
  • 皮膚科
  • 呼吸器疾患

第7章 地域別・国別の分析

  • 世界のペプチド治療薬市場、地域別、実績・予測、2018年～2023年、2023～2028年、2033年
  • 世界のペプチド治療薬市場、国別、実績・予測、2018年～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ペプチド治療薬市場の競合情勢
  • ペプチド治療薬市場の企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • AbbVie Inc.
    • Novartis AG
    • Bristol-Myers Squibb Company

第31章 その他の主要および革新的な企業

  • AstraZeneca plc
  • Sanofi SA
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Eli Lilly and Company
  • Amgen Inc.
  • Novo Nordisk AS
  • Teva Pharmaceuticals Industries Ltd.
  • Bachem Holding AG
  • PolyPeptide Laboratories BV
  • Arcus Biosciences Inc.
  • Anaptys Bio Inc.
  • Endoceutics Inc.
  • Pepscan Therapeutics
  • Peptech Inc.

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r15906

Peptide therapeutics involve using peptides as medicinal treatments. Peptides constitute a distinct group of pharmacological compounds positioned molecularly between proteins and small molecules. Natural peptides serve diverse roles such as hormones, growth factors, neurotransmitters, ion channel ligands, and anti-infectives. Leveraging peptides as therapies allows for targeted cell interaction and modulation of cellular responses, offering a broad spectrum of treatment possibilities.

The primary classifications of peptide therapeutics include generic and branded variants. Branded peptide therapeutics are drugs marketed under the brand names of major pharmaceutical companies that hold the patent for these medications. Branded drugs tend to be more costly than their generic counterparts, as they maintain a distinct brand identity. Peptide therapeutics can be administered through various routes such as parenteral, mucosal, oral, and transdermal. They find applications in treating a wide range of medical conditions, including cancer, cardiovascular diseases, central nervous system disorders, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology issues, respiratory disorders, and acromegaly.

The peptide therapeutics market research report is one of a series of new reports from The Business Research Company that provides peptide therapeutics market statistics, including peptide therapeutics industry global market size, regional shares, competitors with a peptide therapeutics market share, detailed peptide therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the peptide therapeutics industry. This peptide therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The peptide therapeutics market size has grown rapidly in recent years. It will grow from $41.44 billion in 2023 to $45.66 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth observed in the historical period can be attributed to the increasing incidence of chronic diseases, a growing understanding of molecular biology, and expanding applications in oncology.

The peptide therapeutics market size is expected to see rapid growth in the next few years. It will grow to $68.83 billion in 2028 at a compound annual growth rate (CAGR) of 10.8%. The anticipated growth in the forecast period can be attributed to the rising demand for personalized medicine, expanding applications in immunotherapy, advancements in peptide delivery systems, emerging peptide targets in infectious diseases, and an increasing focus on rare diseases. Major trends in the forecast period include technological advancements in peptide synthesis, growing investment and funding, an emphasis on peptide drug safety, market expansion in emerging economies, and the integration of artificial intelligence (AI).

The peptide therapeutics market is poised for growth, primarily fueled by the escalating prevalence of chronic diseases. Chronic diseases, characterized by their prolonged and often incurable nature, are on the rise, driven by factors such as increased tobacco product usage, suboptimal nutrition, physical inactivity, and excessive alcohol consumption. Despite being challenging to cure, chronic diseases can be managed and, in some cases, controlled. The utilization of peptide therapeutics plays a crucial role in both the prevention and treatment of certain chronic diseases. Notably, in January 2023, the National Library of Medicine, a US-based agency, reported a significant projection for the United States, indicating that the number of individuals aged 50 and older with at least one chronic condition is expected to surge by 99.5%, reaching 142.66 million by the year 2050. As a result, the anticipated increase in the prevalence of chronic diseases is set to be a key driver for the growth of the peptide therapeutics market throughout the forecast period.

The growth trajectory of the peptide therapeutics market is expected to be significantly influenced by the increasing size of the geriatric population. Defined as individuals aged 65 years and older, the geriatric population faces a higher prevalence of various health conditions. Peptide therapeutics play a pivotal role in managing and treating these conditions by targeting specific pathways associated with age-related diseases, improving bone density, and mitigating the risk of fractures. Notably, global demographic trends, as highlighted by the World Health Organization in October 2022, indicate that 1 in 6 people will be 60 years or older by 2030, with a projected doubling of this age group to 2.1 billion individuals by 2050. Further emphasizing the impact on specific regions, the UK Parliament's House of Commons Library reported in June 2021 that the senior population in the United Kingdom is expected to increase, constituting 24% of the total population (17.4 million people) by the year 2043. This demographic shift underscores the growing importance of peptide therapeutics in addressing the healthcare needs of the elderly. As a result, the rise in the geriatric population emerges as a significant driver propelling the growth of the peptide therapeutics market in the foreseeable future.

Major companies in the peptide therapeutics market are actively focused on introducing advanced solutions to gain a competitive edge, with a notable emphasis on innovations such as the cell culture process. The cell culture process involves growing cells outside of their natural environment under controlled conditions, which includes isolating cells of interest from living tissue and maintaining them. As an illustrative example, in June 2023, Evonik Industries AG, a German-based specialty chemicals company, launched cQrex KC. Positioned as a next-generation peptide for biopharma applications, cQrex KC is specifically designed for the cell culture process used in the manufacturing of biological drugs. It empowers cell culture process developers to optimize cystine supply and enhance cell culture productivity. Notably, cQrex KC contributes to the development of vaccines, viral vectors, and cell therapies, showcasing a commitment to advancing technologies that support crucial aspects of biopharmaceutical production.

Major companies in the peptide therapeutic market are strategically focused on introducing advanced solutions, with a particular emphasis on innovations such as peptide drug discovery, aiming to gain a competitive edge. Peptide drug discovery involves the process of identifying, designing, and developing therapeutic agents composed of short chains of amino acids, known as peptides. A case in point is Fujitsu Limited, a Japan-based information and communications technology equipment and services company, which, in May 2023, unveiled the Biodrug Design Accelerator. This platform is specifically designed to support peptide drug discovery scientists in pharmaceutical companies throughout the design, make, test, analyze (DMTA) cycles. Operating as a web-based solution, the Biodrug Design Accelerator provides assistance to peptide designers by offering visualization of amino acid sequences. This strategic move reflects a commitment to leveraging advanced technologies to enhance and streamline the peptide drug discovery process, ultimately contributing to advancements in therapeutic solutions.

In August 2021, Bayer, a pharmaceutical company headquartered in Germany, successfully completed the acquisition of Vividion Therapeutics for an undisclosed sum. This strategic move is poised to enhance Bayer's proficiency in small molecule therapeutics and open up new market opportunities. The integration of Vividion Therapeutics brings with it an advanced chemoproteomics platform, significantly bolstering Bayer's capabilities in drug discovery. Vividion Therapeutics, Inc., a biotechnology company based in the United States, specializes in pioneering highly selective small-molecule medicines, particularly targeting traditionally challenging therapeutic areas, thereby aligning with Bayer's commitment to transforming the landscape of human health.

Major companies operating in the peptide therapeutics market report are Pfizer Inc., Jhonson & Jhonson, Abbvie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Sanofi SA, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk AS, Teva Pharmaceuticals Industries Ltd., Bachem Holding AG, PolyPeptide Laboratories BV, Arcus Biosciences Inc., Anaptys Bio Inc., Endoceutics Inc., Pepscan Therapeutics, Peptech Inc., Peptide Logic Inc., SELLAS Life Sciences Group, Ever Neuro Pharma GmbH, Zealand Pharma AG, PepGen Inc., Pepticom S.A., Arexis AB, Peptide Technologies Corporation, SynPeptide Inc., Peptimmune Inc., Merck & Co. Inc.

North America was the largest region in the peptide therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peptide therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peptide therapeutics market includes revenues earned by entities by creating drugs to treat a variety of diseases. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peptide Therapeutics Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peptide therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peptide therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peptide therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Generic; Branded
  • 2) By Route of Administration: Parenteral; Mucosal; Oral; Transdermal
  • 3) By Application: Cancer; Cardiovascular Diseases; Central Nervous Systems; Metabolic Disorders; Infections; Hematological Disorders; Gastrointestinal Disorders; Dermatology; Respiratory Disorders; Acromegaly; Other Applications
  • Companies Mentioned: Pfizer Inc.; Jhonson & Jhonson; AbbVie Inc.; Novartis AG; Bristol-Myers Squibb Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peptide Therapeutics Market Characteristics

3. Peptide Therapeutics Market Trends And Strategies

4. Peptide Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Peptide Therapeutics Market Size and Growth

  • 5.1. Global Peptide Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Peptide Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Peptide Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Peptide Therapeutics Market Segmentation

  • 6.1. Global Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Generic
  • Branded
  • 6.2. Global Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Parenteral
  • Mucosal
  • Oral
  • Transdermal
  • 6.3. Global Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Cancer
  • Cardiovascular Diseases
  • Central Nervous Systems
  • Metabolic Disorders
  • Infections
  • Hematological Disorders
  • Gastrointestinal Disorders
  • Dermatology
  • Respiratory Disorders

7. Peptide Therapeutics Market Regional And Country Analysis

  • 7.1. Global Peptide Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Peptide Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Peptide Therapeutics Market

  • 8.1. Asia-Pacific Peptide Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Peptide Therapeutics Market

  • 9.1. China Peptide Therapeutics Market Overview
  • 9.2. China Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Peptide Therapeutics Market

  • 10.1. India Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Peptide Therapeutics Market

  • 11.1. Japan Peptide Therapeutics Market Overview
  • 11.2. Japan Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Peptide Therapeutics Market

  • 12.1. Australia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Peptide Therapeutics Market

  • 13.1. Indonesia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Peptide Therapeutics Market

  • 14.1. South Korea Peptide Therapeutics Market Overview
  • 14.2. South Korea Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Peptide Therapeutics Market

  • 15.1. Western Europe Peptide Therapeutics Market Overview
  • 15.2. Western Europe Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Peptide Therapeutics Market

  • 16.1. UK Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Peptide Therapeutics Market

  • 17.1. Germany Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Peptide Therapeutics Market

  • 18.1. France Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Peptide Therapeutics Market

  • 19.1. Italy Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Peptide Therapeutics Market

  • 20.1. Spain Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Peptide Therapeutics Market

  • 21.1. Eastern Europe Peptide Therapeutics Market Overview
  • 21.2. Eastern Europe Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Peptide Therapeutics Market

  • 22.1. Russia Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Peptide Therapeutics Market

  • 23.1. North America Peptide Therapeutics Market Overview
  • 23.2. North America Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Peptide Therapeutics Market

  • 24.1. USA Peptide Therapeutics Market Overview
  • 24.2. USA Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Peptide Therapeutics Market

  • 25.1. Canada Peptide Therapeutics Market Overview
  • 25.2. Canada Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Peptide Therapeutics Market

  • 26.1. South America Peptide Therapeutics Market Overview
  • 26.2. South America Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Peptide Therapeutics Market

  • 27.1. Brazil Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Peptide Therapeutics Market

  • 28.1. Middle East Peptide Therapeutics Market Overview
  • 28.2. Middle East Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Peptide Therapeutics Market

  • 29.1. Africa Peptide Therapeutics Market Overview
  • 29.2. Africa Peptide Therapeutics Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Peptide Therapeutics Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Peptide Therapeutics Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Peptide Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Peptide Therapeutics Market Competitive Landscape
  • 30.2. Peptide Therapeutics Market Company Profiles
    • 30.2.1. Pfizer Inc.
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Johnson & Johnson
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. AbbVie Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Novartis AG
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Bristol-Myers Squibb Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Peptide Therapeutics Market Other Major And Innovative Companies

  • 31.1. AstraZeneca plc
  • 31.2. Sanofi SA
  • 31.3. GlaxoSmithKline plc
  • 31.4. Takeda Pharmaceutical Company Limited
  • 31.5. Eli Lilly and Company
  • 31.6. Amgen Inc.
  • 31.7. Novo Nordisk AS
  • 31.8. Teva Pharmaceuticals Industries Ltd.
  • 31.9. Bachem Holding AG
  • 31.10. PolyPeptide Laboratories BV
  • 31.11. Arcus Biosciences Inc.
  • 31.12. Anaptys Bio Inc.
  • 31.13. Endoceutics Inc.
  • 31.14. Pepscan Therapeutics
  • 31.15. Peptech Inc.

32. Global Peptide Therapeutics Market Competitive Benchmarking

33. Global Peptide Therapeutics Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Peptide Therapeutics Market

35. Peptide Therapeutics Market Future Outlook and Potential Analysis

  • 35.1 Peptide Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Peptide Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Peptide Therapeutics Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer